# A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

> **NCT02337855** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 72 (actual)

## Conditions studied

- Schistosomiasis

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Sm-TSP-2/Alhydrogel
- **BIOLOGICAL:** Sm-TSP-2/Alhydrogel/GLA-AF

## Key facts

- **NCT ID:** NCT02337855
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-04
- **Primary completion:** 2017-01-27
- **Final completion:** 2017-01-27
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337855, "A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02337855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*